What OTC Glucose Monitors Are—and What Dexcom Stelo Changes
Over-the-counter glucose monitors are wearable continuous glucose monitoring systems that you can buy without a prescription to track how your blood sugar responds to meals, activity, and daily routines through app-based readings and trend graphs in near real time. Dexcom Stelo’s FDA approval is the clearest sign that this technology is moving from specialist clinics into everyday retail and wellness use. Stelo uses a small sensor worn on the body that measures glucose in the fluid under the skin and sends results to a compatible smartphone or connected device about every 15 minutes. The sensor can last up to 15 days, though wear time may be shorter for children. Unlike prescription CGMs designed for insulin users, Stelo is cleared for people who do not use insulin and is framed as a feedback tool, not a full replacement for clinical diabetes care or medical decision-making.
CGM for Children: New Access, New Responsibilities
Dexcom Stelo FDA approval now extends to children as young as 2 who do not use insulin, making it the first OTC CGM for children and turning glucose tracking into a family technology decision. The sensor pairs with an app on a compatible smartphone or smart device, including a caregiver’s phone, and displays values and trends every 15 minutes. Because Stelo does not send low-glucose alerts and is not for children with problematic hypoglycemia, adult supervision is essential. Schools may face new questions: whether caregiver-connected phones can stay nearby, how Wi‑Fi rules affect the device, and who should respond to readings during class. For healthcare teams, OTC status removes the prescription barrier but not the need for screening. Children who use insulin, have problematic hypoglycemia, or need real-time alerts still require prescription-grade continuous glucose monitoring and direct clinical oversight.
Who OTC CGMs Help Most—and Where Wellness Hype Creeps In
The strongest case for OTC glucose monitors is for people with diabetes who do not use insulin and those with prediabetes who want tighter feedback than occasional lab tests. A recent systematic review found CGM use was linked to lower mean glucose in non-diabetic users, with benefit concentrated in people with prediabetes, but it did not show a clear effect on BMI. For healthy users, the appeal is curiosity and behavior nudges: seeing how certain meals, workouts, or poor sleep influence glucose patterns. That information can guide small lifestyle experiments, but a spike on a glucose tracking app does not automatically mean long-term harm or diagnose disease. Without medical guidance, there is also a risk of over-restrictive eating or anxiety around normal fluctuations, especially for people with a history of disordered eating who are advised to talk with a healthcare provider before using these devices.
Apps, Data, and Privacy: The Hidden Layer of Continuous Glucose Monitoring
Every OTC CGM is both a sensor and a software stack: smartphone apps, cloud accounts, coaching features, and data-sharing settings that matter as much as the hardware. Glucose tracking apps can sync with caregiver phones, backup to the cloud, and connect with other wearable platforms, which raises questions about privacy and security. HIPAA protects data inside traditional healthcare systems, but not every consumer app or wellness subscription is automatically covered. The FTC’s Health Breach Notification Rule may apply when health apps or connected devices outside HIPAA have a security incident. FDA guidance for cyber devices also emphasizes security planning and vulnerability management in premarket submissions. For everyday users, the practical steps are to confirm that an OTC glucose monitor is FDA cleared, read what the app collects and shares, and treat continuous glucose monitoring data as feedback that may or may not enter your formal medical record.
From Medical Tool to Mainstream Wearable: How to Decide if an OTC CGM Is Worth It
As OTC glucose monitors move into pharmacies and wellness platforms, the line between clinical tool and lifestyle gadget can blur. Stelo and Abbott’s Lingo are cleared as feedback systems for people who do not use insulin, not as stand-alone diabetes management replacements. Mainstream adoption could create confusion if users assume continuous glucose monitoring always means medical-grade oversight, or if schools and workplaces treat these like ordinary wearables rather than connected medical devices. Before trying an OTC CGM, ask three questions: Do I have a condition—such as diabetes without insulin use or prediabetes—where continuous feedback could change care plans with my clinician? Am I prepared to interpret app data without overreacting to every spike? And do I understand the privacy, device, and caregiver policies that come with always-on glucose tracking?
